Buy & Sell NextEra Energy, Inc. (NEE) – NextEra Energy, Inc. Price Today
Aura AI Summary
Key Stats
- $179.03BMarket Cap
- UtilitiesSector
- -14.53%3M Drawdown
- $281.43BEnterprise Value
- 2.9%Dividend Yield
- 73 daysTypical Hold Time
NextEra Energy, Inc. (NEE) is currently valued at a market capitalization of $179.03B, with an enterprise value of $281.43B. Over the past 52 weeks, NextEra Energy, Inc. has traded between a low of $69.42 and a high of $97.88, highlighting its annual price range. Over the past three months, NextEra Energy, Inc. has recorded a drawdown of -14.53%, reflecting recent price volatility. NextEra Energy, Inc. offers a dividend yield of 2.9%, with the most recent dividend of $0.62 paid on 05 Jun 26. On average, investors hold NextEra Energy, Inc. for approximately 73 days, indicating typical investor behavior on the platform.
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Most Recent News
Aker BP raises stake in Johan Sverdrup oil field after ownership review
Aker BP ASA has increased its ownership interest in the Johan Sverdrup oil field to 31.7163% from 31.5733% following a redetermination process based on updated technical and production data. This change will be reflected in Aker BP's accounts startin...

Digital Realty launches Malaysia data center operations to boost Southeast Asia's digital and AI infrastructure.
Digital Realty has officially launched its Malaysia operations with a new data center campus in Cyberjaya, aiming to expand its capacity to 32 MW. This development integrates Malaysia into Digital Realty's global network, supporting AI and data-drive...

Novartis to present key Phase III data on Rhapsido for chronic urticaria and food allergy at EAACI 2026.
Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentatio...
